Trial | NCT00501371  Report issue

Title

MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia
Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Terminated

  • Intervention/Treatment

    carotenoid ...

  • Study Participants

    85
Phase III, Randomized, double-blind, parallel placebo-controlled study. Two arms: MCS (30mg/day) vs. placebo.

Subproject MCS-2: alpha-blocker naïve subjects

Subproject MCS-3: subjects responding poorly to alpha-blocker
For MCS-2 This is a double-blind, randomized, placebo-controlled, parallel study where eligible male subjects (age 40, N=188), after a two-week washout period, will be randomized at 1:1 ratio to receive either MCS 30 mg/day or placebo for 12 weeks.

Group A: MCS 30 mg/day for 12 weeks Group B: placebo for 12 weeks

Subjects are limited to those who are currently not being treated medically for BPH or LUTS with alpha-blockers, anti-cholinergics, 5-alpha reductase inhibitors, or hormonal therapeutic agents. For each treatment arm, about 85 subjects eligible for final per protocol analysis will be recruited. Concerning an expected dropout rate of 10%, 188 subjects in total will be recruited onto the study.

For MCS-3 This is a double-blind, randomized, placebo-controlled, add-on, parallel study where eligible male subjects (age 40, N=242), after a two-week washout period, will be randomized at 1:1 ratio to receive either MCS 30 mg/day plus alpha-blocker or placebo plus alpha-blocker for 12 weeks.

Group A: alpha-blocker plus MCS 30 mg/day Group B: alpha-blocker plus placebo

Subjects are limited to those who are currently not being treated medically for BPH or LUTS with anti-cholinergics, 5-alpha reductase inhibitors, or hormonal therapeutic agents. For each treatment arm, about 220 subjects eligible for final per protocol analysis will be recruited. Concerning an expected dropout rate of 10%, 242 subjects in total will be recruited onto the study.

All participating subjects will be advised to maintain a normal diet as they do before joining the study. However, participating subjects are advised to refrain from extra source of carotenoids supplementation and MCS extracts made into a capsule, soft gel, or crude granule extracts.
Study Started
Jul 31
2007
Primary Completion
Oct 31
2009
Study Completion
Oct 31
2009
Last Update
Dec 14
2011
Estimate

Drug MCS

soft-gel capsule, 15 mg/cap., Qd, 12 weeks

  • Other names: MUS

Drug Placebo

soft-gel capsule, Qd, 12 weeks

  • Other names: MUS

MCS Active Comparator

Group A: MCS 30 mg/day for 12 weeks

Placebo Placebo Comparator

Placebo, 2 capsules per day

Criteria 

Inclusion criteria for subproject MCS-2

Age ≧ 40 years old.
Not being treated for BPH or LUTS with Alpha-blocker, anti-cholinergics, 5-alpha reductase inhibitors, or hormonal agents.
PSA≦4 ng/ml within 4 weeks of V1 and no pathologically-proven prostate cancer.
No known malignancy, except cancers without signs of recurrence for > 5 years and no need for further anti-cancer treatment.
AST/ALT≦3X UNL.
creatinine≦3X UNL.
Subjects who sign the informed consent form.

Exclusion criteria

Subjects' LUTS are not BPH-related but are associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures.
Have been treated with pelvis irradiation or pelvic surgery.
Plan to undergo any invasive procedures within the study period, such as, prostate surgery, prostate biopsy, cystourethroscopy, pelvic surgery, laparotomy, or any procedures needing urethral catheterization.
Participating in another investigational agent study in the past 12 weeks or are going to do so during the study period.
Active infection or inflammation.
Considered ineligible by the investigators.

Inclusion criteria for subproject MCS-3

Age≧40 years old.
The alpha-blocker dosage used should be as high as subjects can tolerate.
No known malignancy, except cancers without signs of recurrence for > 5 years and no need for further anti-cancer treatment.
PSA≦10.0 ng/ml without pathologically-proven prostate cancer or other cancers. Prostate biopsy is mandatory > 12 weeks before screening, if PSA is≧4 ng/ml to rule out prostate cancer.
AST/ALT≦3X UNL.
Creatinine≦3X UNL.
Subjects who sign the informed consent form.

Exclusion criteria

Subjects' LUTS are not BPH-related but associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures.
Subjects who have been treated with pelvis irradiation or pelvic surgery.
PSA > 10.0 ng/ml, abnormal DRE of the prostate or any suspicion of prostate malignancy. However, those who have a negative prostate biopsy are allowed.
Active infection or inflammation.
Considered ineligible by the investigators.
No Results Posted